abstract |
The present invention relates to novel aminoisoquinoline compounds, compositions thereof, protein kinase inhibitors of these compounds, as defined herein, and the treatment of Raf kinases, particularly BRAF V600E kinase related diseases or disorders, such as cancer. Provide use as an agent. Furthermore, the present invention includes a process for producing these novel aminoisoquinoline compounds. |